Global Companion Diagnostic Tests in Oncology Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI03241555

Publication Date:

March 4, 2024

Pages:

115

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Companion Diagnostic Tests in Oncology market size was valued at US$ 3814.3 million in 2023. With growing demand in downstream market, the Companion Diagnostic Tests in Oncology is forecast to a readjusted size of US$ 7364.7 million by 2030 with a CAGR of 9.9% during review period.
The research report highlights the growth potential of the global Companion Diagnostic Tests in Oncology market. Companion Diagnostic Tests in Oncology are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Companion Diagnostic Tests in Oncology. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Companion Diagnostic Tests in Oncology market.
Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Companion Diagnostic Tests in Oncology market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Companion Diagnostic Tests in Oncology market. It may include historical data, market segmentation by Type (e.g., Protein Detection, DNA Detection), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Companion Diagnostic Tests in Oncology market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Companion Diagnostic Tests in Oncology market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Companion Diagnostic Tests in Oncology industry. This include advancements in Companion Diagnostic Tests in Oncology technology, Companion Diagnostic Tests in Oncology new entrants, Companion Diagnostic Tests in Oncology new investment, and other innovations that are shaping the future of Companion Diagnostic Tests in Oncology.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Companion Diagnostic Tests in Oncology market. It includes factors influencing customer ' purchasing decisions, preferences for Companion Diagnostic Tests in Oncology product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Companion Diagnostic Tests in Oncology market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Companion Diagnostic Tests in Oncology market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Companion Diagnostic Tests in Oncology market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Companion Diagnostic Tests in Oncology industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Companion Diagnostic Tests in Oncology market.
Market Segmentation:
Companion Diagnostic Tests in Oncology market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Protein Detection
DNA Detection
Segmentation by application
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Institutes
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Roche
Genomic Health
QIAGEN
Agilent
Agendia
BioMerieux
Illumina
Siemens Healthcare
Thermo Fisher

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Companion Diagnostic Tests in Oncology Market Size 2019-2030
2.1.2 Companion Diagnostic Tests in Oncology Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Companion Diagnostic Tests in Oncology Segment by Type
2.2.1 Protein Detection
2.2.2 DNA Detection
2.3 Companion Diagnostic Tests in Oncology Market Size by Type
2.3.1 Companion Diagnostic Tests in Oncology Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Companion Diagnostic Tests in Oncology Market Size Market Share by Type (2019-2024)
2.4 Companion Diagnostic Tests in Oncology Segment by Application
2.4.1 Pharmaceutical & Biotechnology Companies
2.4.2 Medical Device Companies
2.4.3 Research Institutes
2.4.4 Others
2.5 Companion Diagnostic Tests in Oncology Market Size by Application
2.5.1 Companion Diagnostic Tests in Oncology Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Companion Diagnostic Tests in Oncology Market Size Market Share by Application (2019-2024)
3 Companion Diagnostic Tests in Oncology Market Size by Player
3.1 Companion Diagnostic Tests in Oncology Market Size Market Share by Players
3.1.1 Global Companion Diagnostic Tests in Oncology Revenue by Players (2019-2024)
3.1.2 Global Companion Diagnostic Tests in Oncology Revenue Market Share by Players (2019-2024)
3.2 Global Companion Diagnostic Tests in Oncology Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Companion Diagnostic Tests in Oncology by Regions
4.1 Companion Diagnostic Tests in Oncology Market Size by Regions (2019-2024)
4.2 Americas Companion Diagnostic Tests in Oncology Market Size Growth (2019-2024)
4.3 APAC Companion Diagnostic Tests in Oncology Market Size Growth (2019-2024)
4.4 Europe Companion Diagnostic Tests in Oncology Market Size Growth (2019-2024)
4.5 Middle East & Africa Companion Diagnostic Tests in Oncology Market Size Growth (2019-2024)
5 Americas
5.1 Americas Companion Diagnostic Tests in Oncology Market Size by Country (2019-2024)
5.2 Americas Companion Diagnostic Tests in Oncology Market Size by Type (2019-2024)
5.3 Americas Companion Diagnostic Tests in Oncology Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Companion Diagnostic Tests in Oncology Market Size by Region (2019-2024)
6.2 APAC Companion Diagnostic Tests in Oncology Market Size by Type (2019-2024)
6.3 APAC Companion Diagnostic Tests in Oncology Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Companion Diagnostic Tests in Oncology by Country (2019-2024)
7.2 Europe Companion Diagnostic Tests in Oncology Market Size by Type (2019-2024)
7.3 Europe Companion Diagnostic Tests in Oncology Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Companion Diagnostic Tests in Oncology by Region (2019-2024)
8.2 Middle East & Africa Companion Diagnostic Tests in Oncology Market Size by Type (2019-2024)
8.3 Middle East & Africa Companion Diagnostic Tests in Oncology Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Companion Diagnostic Tests in Oncology Market Forecast
10.1 Global Companion Diagnostic Tests in Oncology Forecast by Regions (2025-2030)
10.1.1 Global Companion Diagnostic Tests in Oncology Forecast by Regions (2025-2030)
10.1.2 Americas Companion Diagnostic Tests in Oncology Forecast
10.1.3 APAC Companion Diagnostic Tests in Oncology Forecast
10.1.4 Europe Companion Diagnostic Tests in Oncology Forecast
10.1.5 Middle East & Africa Companion Diagnostic Tests in Oncology Forecast
10.2 Americas Companion Diagnostic Tests in Oncology Forecast by Country (2025-2030)
10.2.1 United States Companion Diagnostic Tests in Oncology Market Forecast
10.2.2 Canada Companion Diagnostic Tests in Oncology Market Forecast
10.2.3 Mexico Companion Diagnostic Tests in Oncology Market Forecast
10.2.4 Brazil Companion Diagnostic Tests in Oncology Market Forecast
10.3 APAC Companion Diagnostic Tests in Oncology Forecast by Region (2025-2030)
10.3.1 China Companion Diagnostic Tests in Oncology Market Forecast
10.3.2 Japan Companion Diagnostic Tests in Oncology Market Forecast
10.3.3 Korea Companion Diagnostic Tests in Oncology Market Forecast
10.3.4 Southeast Asia Companion Diagnostic Tests in Oncology Market Forecast
10.3.5 India Companion Diagnostic Tests in Oncology Market Forecast
10.3.6 Australia Companion Diagnostic Tests in Oncology Market Forecast
10.4 Europe Companion Diagnostic Tests in Oncology Forecast by Country (2025-2030)
10.4.1 Germany Companion Diagnostic Tests in Oncology Market Forecast
10.4.2 France Companion Diagnostic Tests in Oncology Market Forecast
10.4.3 UK Companion Diagnostic Tests in Oncology Market Forecast
10.4.4 Italy Companion Diagnostic Tests in Oncology Market Forecast
10.4.5 Russia Companion Diagnostic Tests in Oncology Market Forecast
10.5 Middle East & Africa Companion Diagnostic Tests in Oncology Forecast by Region (2025-2030)
10.5.1 Egypt Companion Diagnostic Tests in Oncology Market Forecast
10.5.2 South Africa Companion Diagnostic Tests in Oncology Market Forecast
10.5.3 Israel Companion Diagnostic Tests in Oncology Market Forecast
10.5.4 Turkey Companion Diagnostic Tests in Oncology Market Forecast
10.5.5 GCC Countries Companion Diagnostic Tests in Oncology Market Forecast
10.6 Global Companion Diagnostic Tests in Oncology Forecast by Type (2025-2030)
10.7 Global Companion Diagnostic Tests in Oncology Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Abbott
11.1.1 Abbott Company Information
11.1.2 Abbott Companion Diagnostic Tests in Oncology Product Offered
11.1.3 Abbott Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Abbott Main Business Overview
11.1.5 Abbott Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Companion Diagnostic Tests in Oncology Product Offered
11.2.3 Roche Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Genomic Health
11.3.1 Genomic Health Company Information
11.3.2 Genomic Health Companion Diagnostic Tests in Oncology Product Offered
11.3.3 Genomic Health Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Genomic Health Main Business Overview
11.3.5 Genomic Health Latest Developments
11.4 QIAGEN
11.4.1 QIAGEN Company Information
11.4.2 QIAGEN Companion Diagnostic Tests in Oncology Product Offered
11.4.3 QIAGEN Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 QIAGEN Main Business Overview
11.4.5 QIAGEN Latest Developments
11.5 Agilent
11.5.1 Agilent Company Information
11.5.2 Agilent Companion Diagnostic Tests in Oncology Product Offered
11.5.3 Agilent Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Agilent Main Business Overview
11.5.5 Agilent Latest Developments
11.6 Agendia
11.6.1 Agendia Company Information
11.6.2 Agendia Companion Diagnostic Tests in Oncology Product Offered
11.6.3 Agendia Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Agendia Main Business Overview
11.6.5 Agendia Latest Developments
11.7 BioMerieux
11.7.1 BioMerieux Company Information
11.7.2 BioMerieux Companion Diagnostic Tests in Oncology Product Offered
11.7.3 BioMerieux Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 BioMerieux Main Business Overview
11.7.5 BioMerieux Latest Developments
11.8 Illumina
11.8.1 Illumina Company Information
11.8.2 Illumina Companion Diagnostic Tests in Oncology Product Offered
11.8.3 Illumina Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Illumina Main Business Overview
11.8.5 Illumina Latest Developments
11.9 Siemens Healthcare
11.9.1 Siemens Healthcare Company Information
11.9.2 Siemens Healthcare Companion Diagnostic Tests in Oncology Product Offered
11.9.3 Siemens Healthcare Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Siemens Healthcare Main Business Overview
11.9.5 Siemens Healthcare Latest Developments
11.10 Thermo Fisher
11.10.1 Thermo Fisher Company Information
11.10.2 Thermo Fisher Companion Diagnostic Tests in Oncology Product Offered
11.10.3 Thermo Fisher Companion Diagnostic Tests in Oncology Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Thermo Fisher Main Business Overview
11.10.5 Thermo Fisher Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂